<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo


                           July 6, 2020

       Asa Abeliovich, M.D., Ph.D.
       President and Chief Executive Officer
       Prevail Therapeutics Inc.
       430 East 29th Street, Suite 1520
       New York, New York 10016

                                                        Re: Prevail
Therapeutics Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed July 1, 2020
                                                            File No. 333-239612

       Dear Dr. Abeliovich:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Chris
Edwards at (202) 551-6761 with any questions.


                           Sincerely,


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Alison A. Haggerty
</TEXT>
</DOCUMENT>